Similarly, Lynch syndrome patients, characterized by mismatch repair (MMR) deficiencies that predispose them to colorectal, endometrial, and various extracolonic neoplasms, stand to gain from OC’s documented capacity to suppress pro-tumorigenic inflammatory pathways, including PAR-2-associated pathways [80,133,145]. This evidence concerns the gene F2RL1 and Lynch syndrome.